Alaunos Therapeutics has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000 following a private placement financing. As a result, the previously scheduled delisting hearing has been cancelled and the company's common stock will continue to trade on The Nasdaq Capital Market.
Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, due to continued non-compliance with the $2.5 million minimum stockholders' equity requirement. The company has requested a hearing before the Nasdaq Hearings Panel, currently scheduled for November 10, 2026, which has stayed any delisting action pending the outcome.
Alaunos Therapeutics M&A Deal with Velaris Therapeutics, Inc.
Alaunos Therapeutics completed the acquisition of Velaris Therapeutics through a two-step merger process, making Velaris a wholly owned subsidiary. As consideration, Alaunos issued 105,286 shares of Series B Preferred Stock and 33,054 shares of Series C Preferred Stock to Velaris stockholders, which are convertible into common stock subject to shareholder approval. Following the deal, Alaunos plans to change its name to Velaris Therapeutics, Inc. and effect a reverse stock split.
Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, for failing to maintain the minimum $2.5 million stockholders' equity requirement. The company intends to request a hearing before the Nasdaq Hearings Panel to stay the delisting and is currently evaluating strategic alternatives to regain compliance.
Alaunos Therapeutics entered into a securities purchase agreement for a registered direct offering of 380,469 shares of common stock and 386,654 pre-funded warrants. The offering was priced at $1.46 per share, generating aggregate gross proceeds of approximately $1.12 million. The company intends to use the net proceeds for general corporate purposes and working capital.